TSC causes epilepsy in up to 85 % of patients, and up to 60 % of those patients do not respond to standard anti-seizure medicines
The company has tied up with OrbiMed as a financial partner for global reach
The profits were bolstered by the Boehringer Ingelheim MEK program income
Formulation business grew by 15 per cent in the quarter
This robust performance is a testimony of the company's agility, resilience and strong execution capabilities during these difficult times
A globally approved pen filled by mass technology provides a safer self- administration fertility solution
A veteran in cell therapy and oncology commercialisation
Phase II trial will evaluate the safety and efficacy of ASC40 in patients with moderate to severe acne
Board declares interim dividend of Rs 2 per equity share
All India Institute of Ayurveda hosts ministers and showcase their achievements
Subscribe To Our Newsletter & Stay Updated
